These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21474720)

  • 21. Resistance to anti-HCV protease inhibitors.
    Thompson AJ; Locarnini SA; Beard MR
    Curr Opin Virol; 2011 Dec; 1(6):599-606. PubMed ID: 22440917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection.
    Sethi N; Tapper EB; Vong A; Sethi S; Rourke M; Afdhal NH
    J Viral Hepat; 2015 Dec; 22(12):974-6. PubMed ID: 26010946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 3 study results released for telaprevir and HCV.
    AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
    [No Abstract]   [Full Text] [Related]  

  • 24. [Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively].
    Kozielewicz D; Halota W; Dybowska D
    Przegl Epidemiol; 2012; 66(1):49-54. PubMed ID: 22708298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New HCV drugs trigger race for more tolerable therapies.
    Williams SC
    Nat Med; 2011 Dec; 17(12):1526. PubMed ID: 22146431
    [No Abstract]   [Full Text] [Related]  

  • 26. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A major advance in treating hepatitis C.
    Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):6. PubMed ID: 22216468
    [No Abstract]   [Full Text] [Related]  

  • 28. Excitement grows for potential revolution in hepatitis C virus treatment.
    Opar A
    Nat Rev Drug Discov; 2010 Jul; 9(7):501-3. PubMed ID: 20592732
    [No Abstract]   [Full Text] [Related]  

  • 29. What about us? Recent advances in the treatment of chronic hepatitis C threaten to leave some parts of the world behind.
    Ahmed F
    J Viral Hepat; 2013 May; 20(5):367-8. PubMed ID: 23565620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.
    Jacobson IM; Pawlotsky JM; Afdhal NH; Dusheiko GM; Forns X; Jensen DM; Poordad F; Schulz J
    J Viral Hepat; 2012 May; 19 Suppl 2():1-26. PubMed ID: 22404758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Telaprevir-induced pityriasis rubra pilaris].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 May; 140(5):414-5. PubMed ID: 23663723
    [No Abstract]   [Full Text] [Related]  

  • 32. Protease inhibitors in hepatitis C: from chronic disease to cure.
    Iqbal M; McCormick PA
    Ir Med J; 2011 Sep; 104(8):230-1. PubMed ID: 22125874
    [No Abstract]   [Full Text] [Related]  

  • 33. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
    Chen KX; Njoroge FG
    Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
    [No Abstract]   [Full Text] [Related]  

  • 34. [Conclusions].
    Pineda JA
    Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():49-50. PubMed ID: 24063903
    [No Abstract]   [Full Text] [Related]  

  • 35. The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
    Gentile I; Carleo MA; Borgia F; Castaldo G; Borgia G
    Expert Opin Investig Drugs; 2010 Jan; 19(1):151-9. PubMed ID: 20001560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HCV protease inhibitors bring new options for patients.
    Traynor K
    Am J Health Syst Pharm; 2011 Aug; 68(15):1372, 1374, 1379. PubMed ID: 21785015
    [No Abstract]   [Full Text] [Related]  

  • 37. Emerging therapeutic options for the management of hepatitis C infection.
    Thompson JR
    World J Gastroenterol; 2014 Jun; 20(23):7079-88. PubMed ID: 24966581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
    Kronenberger B; Zeuzem S
    Curr Gastroenterol Rep; 2009 Feb; 11(1):15-21. PubMed ID: 19166654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C.
    Smith LS; Nelson M; Naik S; Woten J
    Ann Pharmacother; 2011 May; 45(5):639-48. PubMed ID: 21558488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.